Your browser version may not work well with NCBI's Web applications. More information here...
1: Curr Opin Mol Ther. 2007 Apr;9(2):197-203.Links

Drug evaluation: zanolimumab, a human monoclonal antibody targeted against CD4.

Assaf C, Sterry W.

Skin Cancer Center Charité, Department of Dermatology, Venereology and Allergy, Charité-Universitätsmedizin Berlin, Fabeckstr 60-62, 14195 Berlin, Germany. chalid.assaf@charite.de

Merck Serono SA, under license from Genmab A/S and Medarex Inc, is developing zanolimumab, a human mAb targeted against CD4, for the potential treatment of cutaneous (CTCL) and noncutaneous (NCTCL) T-cell lymphomas. Zanolimumab is currently undergoing phase III clinical trials for CTCL and phase II clinical trials for NCTCL.

PMID: 17458175 [PubMed - indexed for MEDLINE]